This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 956851.

COLOTAN new published article on the challenges and opportunities when managing the clinical effects of drug-induced intestinal dysbiosis

Managing the clinical effects of drug-induced intestinal dysbiosis with a focus to antibiotics: challenges and opportunities

L. Gnatzy, G. Ismailos, M. Vertzoni, C. Reppas


The term “intestinal dysbiosis” is used for indicating change(s) of the intestinal microbiota which have been associated with the development of diseases and the deterioration of disease treatments in humans. In this review, documented clinical effects of drug-induced intestinal dysbiosis are briefly presented, and methodologies which could be considered for the management of drug-induced intestinal dysbiosis based on clinical data are critically reviewed. Until relevant methodologies are optimized and/or their effectiveness to the general population is confirmed, and, since drug-induced intestinal dysbiosis refers predominantly to antibiotic-specific intestinal dysbiosis, a pharmacokinetically-based approach for mitigating the impact of antimicrobial therapy on intestinal dysbiosis is proposed.

Read the full article here: